AU2022268720A1 - Compositions and methods for the treatment of depression - Google Patents

Compositions and methods for the treatment of depression Download PDF

Info

Publication number
AU2022268720A1
AU2022268720A1 AU2022268720A AU2022268720A AU2022268720A1 AU 2022268720 A1 AU2022268720 A1 AU 2022268720A1 AU 2022268720 A AU2022268720 A AU 2022268720A AU 2022268720 A AU2022268720 A AU 2022268720A AU 2022268720 A1 AU2022268720 A1 AU 2022268720A1
Authority
AU
Australia
Prior art keywords
aticaprant
treatment
patient
anhedonia
baseline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022268720A
Other languages
English (en)
Inventor
Wayne C. Drevets
Srihari Gopal
Iva Kezic
Chakradhar Lagishetty
Rama Melkote
Darrel Pemberton
Vanina Popova
Adam SAVITZ
Mark Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/307,858 external-priority patent/US11266627B1/en
Priority claimed from US17/670,123 external-priority patent/US12161622B2/en
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of AU2022268720A1 publication Critical patent/AU2022268720A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)
AU2022268720A 2021-05-04 2022-05-03 Compositions and methods for the treatment of depression Pending AU2022268720A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17/307,858 2021-05-04
US17/307,858 US11266627B1 (en) 2021-05-04 2021-05-04 Compositions and methods for the treatment of depression
US17/670,123 2022-02-11
US17/670,123 US12161622B2 (en) 2021-05-04 2022-02-11 Compositions and methods for the treatment of depression
US202263313792P 2022-02-25 2022-02-25
US63/313,792 2022-02-25
PCT/IB2022/054085 WO2022234457A1 (en) 2021-05-04 2022-05-03 Compositions and methods for the treatment of depression

Publications (1)

Publication Number Publication Date
AU2022268720A1 true AU2022268720A1 (en) 2023-12-21

Family

ID=81654924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022268720A Pending AU2022268720A1 (en) 2021-05-04 2022-05-03 Compositions and methods for the treatment of depression

Country Status (16)

Country Link
EP (1) EP4333835A1 (https=)
JP (1) JP2024516297A (https=)
KR (1) KR20240004857A (https=)
AU (1) AU2022268720A1 (https=)
BR (1) BR112023023030A2 (https=)
CA (1) CA3219079A1 (https=)
CL (1) CL2023003259A1 (https=)
CO (1) CO2023015571A2 (https=)
IL (1) IL308221A (https=)
JO (1) JOP20230276A1 (https=)
MX (1) MX2023013040A (https=)
PE (1) PE20241784A1 (https=)
PH (1) PH12023552963A1 (https=)
TW (1) TW202313003A (https=)
UY (1) UY39754A (https=)
WO (1) WO2022234457A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2023231493A1 (en) * 2022-03-07 2024-10-24 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170550A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Polymorph forms of aticaprant for use in treating major depressive disorder
WO2024216046A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating anhedonia
WO2024216061A1 (en) * 2023-04-13 2024-10-17 Neumora Therapeutics, Inc. Methods of treating depression and anhedonia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345637B2 (ja) 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト

Also Published As

Publication number Publication date
CO2023015571A2 (es) 2023-11-30
EP4333835A1 (en) 2024-03-13
IL308221A (en) 2024-01-01
CL2023003259A1 (es) 2024-05-31
WO2022234457A1 (en) 2022-11-10
PH12023552963A1 (en) 2024-03-11
PE20241784A1 (es) 2024-09-06
MX2023013040A (es) 2024-01-05
UY39754A (es) 2022-11-30
JP2024516297A (ja) 2024-04-12
KR20240004857A (ko) 2024-01-11
TW202313003A (zh) 2023-04-01
BR112023023030A2 (pt) 2024-02-15
CA3219079A1 (en) 2022-11-10
JOP20230276A1 (ar) 2023-11-02

Similar Documents

Publication Publication Date Title
US11266627B1 (en) Compositions and methods for the treatment of depression
US12150929B2 (en) Compositions and methods for the treatment of depression
AU2022268720A1 (en) Compositions and methods for the treatment of depression
US11980596B2 (en) Delivery of esketamine for the treatment of depression
CA3086478A1 (en) Esketamine for the treatment of depression
US20240277608A1 (en) Esketamine for the treatment of depression
US12201610B2 (en) Compositions comprising aticaprant
US20250221960A1 (en) Compositions and methods for the treatment of depression
US20250177350A1 (en) Compositions and methods for the treatment of depression
US20240238245A1 (en) Compositions and methods for the treatment of depression
US20250064779A1 (en) Compositions and methods for the treatment of depression
EA050800B1 (ru) Композиции и способы лечения депрессии